WHO to World: The Foundation of Modern Medicine is Crumbling.
WHO to World: The Foundation of Modern Medicine is Crumbling.

WHO to World: The Foundation of Modern
Medicine is Crumbling

By Tristan A Cogan, BSc (Hons) PhD, Natureza Antimicrobial Projects Manager

WHO to World: The Foundation of Modern Medicine is Crumbling

Tristan A Cogan, BSc (Hons) PhD, Natureza Antimicrobial Projects Manager

The WHO has recognised a number of antibiotic-resistant pathogens as posing the greatest threat to human health. It further concluded that mortality and morbidity from resistant infections is on the rise globally, the clinical anti-bacterial pipeline remains insufficient, and the pipeline outlook remains bleak (WHO 2019). A recent Wellcome Trust report concludes that it is ‘no exaggeration to say that antibiotics are the foundations of modern medicine. But these foundations are crumbling’ (Wellcome Trust 2020). This is exacerbated by economic disincentives. It typically takes 10-15 years and over $1 Billion to produce a new antibiotic.

The fact that bacteria can develop resistance within months of a new antibiotic being deployed has acted as a powerful disincentive for antibiotic development, with only two new classes being developed in the last 40 years. In the laboratory this has been illustrated to occur in a matter of days following the exposure of non-resistant bacteria to an agent in agar, resulting in the evolution of stronger resistance over time (Baym et al 2016). It is clear than new classes of antibiotics with novel targets need to be developed, but also that these need to present a barrier to the development of antibiotic resistance.

The majority of the bacteria needing new antibiotics to be developed as a critical or high priority are Gram-negative – the ESKAPE pathogens – but a minority of Gram-positives, such as vancomycin-resistant Enterococcus faecium, are also high priority.
Carboxylic acids and their derivatives are known to have weak antimicrobial activity against Gram-positive bacteria in their native state (Casillas-Vargas et al. 2021), with activity against Gram-negative organisms only seen at very high concentrations (Kabara et al. 1972), which make them impractical for use as a therapeutic agent. Alkyl amine and amide derivatives of fatty acids (with nitrogen atoms in or attached to the hydrocarbon chain) have improved activity, with some showing weak activity against Gram-negatives, but have chronic effects making them unsuitable for use as a human chemotherapeutic agent (Anonymous 1999).

Casillas-Vargas et al. (2021) suggested that fatty acids could form the basis of a new generation of antimicrobial agents due to their ability to act directly on bacteria and to synergise with existing antibiotics. Lam et al. (2016) had previously shown that a number of fatty acids could be formulated as phospholipid liposomes, and that these showed antibacterial activity, but that absorption into eukaryotic membranes and cytotoxic activity was a problem with extended contact, meaning that such preparations were likely to be limited to topical usage.
Bacteria have a long history of exposure to carboxylic acids, with chain lengths of up to C18 being present in milk and animal and plant tissues. Despite centuries of exposure to inhibitory or subinhibitory concentrations, carboxylic acids at high concentrations are still reliable food preservation agents (Vazquez et al 2011), with no indication that resistance has ever developed.

Carboxylic acids act on the membrane of bacteria, disrupting the function of the membrane and altering fluidity (Parsons et al 2012) and altering cell signalling pathways (Ibarguren et al 2014). It is also suggested that production of ROS, DNA/RNA/protein synthesis inhibition and metabolic inhibition could also be mechanisms of action (Casillas-Vargas et al. (2021).

These substances are readily absorbed into the skin and mucous membranes. This property is desirable in a topical agent, but limits their efficacy in internal usage, where rapid absorbance and turnover by eukaryotic cells means that they cannot reach a distal site of action.
Nanoparticle encapsulation has been used in recent years to protect drugs from off-target absorbance, and has been used to deliver higher concentrations of antibiotics to bacteria than would be possible using the agents in their native state. This has been shown to be effective in overcoming low level resistance to agents in MRSA (Scolari et al) and in Mycobacterium (About aleb et al).

Here we show that chitosan nanoparticle encapsulation of C12 fatty acids renders them active against Gram-positive bacteria at lower concentration than free fatty acids. We show that chemical decoration of the chitosan enables these fatty acids extend their spectrum of activity to encompass the Gram-negative ESKAPE pathogens, with activity seen against highly antibiotic resistant bacteria.

Finally, we demonstrate that these compounds are non-toxic and that no resistance develops on long term exposure of bacteria to the compounds either in broth using the spatiotemporal evolution method of Baym et al.

We suggest that these encapsulated carboxylic acids represent a usable new class of antibiotics with no likelihood of rapid bacterial resistance developing.

Natureza® Develops a Transformative New Class of Antibiotics that Overcomes Bacterial Resistance

Natureza® Develops a Transformative New Class of Antibiotics that Overcomes Bacterial Resistance

This work has been submitted for publication in a peer-reviewed journal and is protected by at least one US patent as well as several patent applications.

Lack of New Antibiotics Threatens Global Efforts to Contain Drug-Resistant Fnfections - WHO 2020

Lack of New Antibiotics Threatens Global Efforts to Contain Drug-Resistant Fnfections

“Never has the threat of antimicrobial resistance been more immediate and the need for solutions more urgent,” says Dr Tedros Adhanom Ghebreyesus, Director-General of WHO.

LEARN MORE

Share this post

2022-08-03T13:48:25+00:00
Go to Top